Abstract The emergence of a large number of antimicrobialresistant organisms is a cause for concern. Nature is historically the source of drugs; indeed a considerable number of drugs have been developed from microorganisms, and are now used daily in the treatment of infectious diseases. However, the introduction to the pharmaceutical market of new therapeutic molecules has decreased during the last two decades. In this review, the genus Micromonospora is proposed as a biofactory for production of new antibiotics. The genus Micromonospora has been investigated extensively and more than 100 antibiotics have been isolated from diverse Micromonospora strains. In addition, recent developments in analytical, biological and bioinformatics screening tools used in the discovery of new therapeutic compounds are described. It may be possible to revive formerly used antibiotics produced by Micromonospora and study of this genus may facilitate discovery of novel bioactive molecules.
Introduction
The emergence of antimicrobial-resistant organisms is a major problem in the treatment of many infectious diseases [1] [2] [3] . In December 2014, a report commissioned by the British Prime Minister, David Cameron, under the title "Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations", was published. This report estimates that drug-resistant infections will cause 10 million deaths additional annually and an economic loss of over 100 trillion USD in 2050 [4, 5] . However, the introduction of new antibiotics has significantly decreased during the last 20 years, because of limitations of drug discovery programs and an inappropriate economic-regulatory environment [6] [7] [8] [9] . Natural products are an essential source of compounds for drug discovery. In addition to plants, microorganisms have provided a large number of therapeutic compounds [10, 11] . Recently, a team led by Kim Lewis of Northeastern University in Boston, Massachusetts, published in Nature the discovery via a new technology of a new antibiotic, teixobactin, which has a novel mechanism of action. This was the first new antibiotic of high therapeutic potential discovered since 1987 [8, 12] .
Subsequent to the discovery of gentamicin, the genus Micromonospora became an important source in the drug discovery process. More than 740 antibiotics have been isolated from Micromonospora strains [13, 14] . In this review, we summarize the most important antibiotics produced by Micromonospora species, and provide an update on the various strategies that can be used for development of new antibiotics from this genus.
The Genus Micromonospora
The genus Micromonospora, a member of the family Micromonosporaceae, was initially described by Ørskov in 1923 [15] [16] [17] . The species belonging to this genus are Gram-positive bacteria, aerobic to microaerophilic, chemoorganotrophic, sensitive to pH below 5.0 and have optimal temperatures between 20 and 40°C. Several strains produce carotenoid mycelial pigments, resulting in yellow, red, orange, brown, purple or black colonies. As its name suggests, this genus produces single spores directly attached to substrate mycelium or carried on short sporophores. The cell wall of Micromonospora contains meso-diaminopimelic acid and/or 3-OH-diaminopimelic acid. The major phospholipids are phosphatidylethanolamine, phosphatidylinositol and phosphatidylinositol mannosides [16, 17] . The first species of this genus, Micromonospora chalcea, was isolated by Foulerton in 1905 and named Streptothrix chalceae [18] . This remained the only known strain among the actinomycetes bearing the generic name Micromonospora until Jensen in 1930 described a large number of soil microorganisms that corresponded with Ørskov's description [19] . At the time of writing, the genus consisted of 61 validly named species (http://www.bacterio.net) [20] , in addition to recently described species; e.g., M. spongicola [21] , M. jinlongensis [22] , M. zeae [23] , M. maoerensis [24] , M. endophytica [25] , M. palomenae [26] , M. harpali [26] , M. oryzae [27] , M. vulcania [28] , M. fluostatini [29] , M. nickelidurans [30] and M. zhanjiangensis [31] .
Antibiotics Derived from the Genus Micromonospora
Actinomycetes are most important biofactory for production of therapeutic secondary metabolites, and most antibiotic discovery research focuses on the isolation of novel secondary metabolites from actinomycetes. After the discovery of gentamicin, the genus Micromonospora became an important source of natural molecules. Table 1 shows antibiotics isolated from strains of the genus Micromonospora. It summarizes the chemical class, producer strain, source of isolation, the year and biological activity from Micromonosporin, an antibiotic isolated in 1947 by Waksman et al. [32] , to the recently discovered compounds such as Neomacquarimicin [33] .
Many aminoglycosides are used in the treatment of infectious diseases caused by Gram-positive and -negative bacteria. The mechanism of action is mediated by targeting the bacterial ribosome. Aminoglycosides bind to the A-site of the ribosome and interrupt protein synthesis. Aminoglycosides are produced by Streptomyces and soil Micromonospora strains [34] [35] [36] [37] [38] [39] .
Gentamicins are the most famous antibiotics produced by the genus Micromonospora [40] . The success of this mixture of aminoglycosides is based on its broad-spectrum activity against Gram-positive and -negative bacteria. The antibiotic mixture was isolated for the first time from two strains: M. echinospora (formerly purpurea) NRRL 2953 and M. echinospora NRRL 2985 from a soil sample in New York, USA [40] [41] [42] . Gentamicins are a water-soluble antibiotic complex, the main constituents being the gentamicin C complex C1, C2, C1a, C2a, and C2b. The chemical structure of this compound is characterized by a central diaminogenouscyclitol (2-deoxystreptamine (2DOS) 4,6-disubstituted with the auxiliary sugars garosamine and purpurosamine, Fig. 1A . In addition to the gentamicin C complex, many minor components, such as gentamicins A, B, and X, have been used as starting materials for the development of antiprotozoal drugs [43, 44] . Gentamicin was introduced into the pharmaceutical market in 1971 and has subsequently been used for diverse medical applications [45] . Currently, gentamicin is included on the essential drug list of the World Health Organization [46] . In addition, new gentamicin-conjugants exhibit antiviral effects (anti-HIV) [43, 44] , and can also be used in genetic therapeutic approaches [47] . Furthermore, gentamicin has been applied successfully in agriculture [48] .
Antibiotic G-418 (geneticin) is similar in structure to gentamicin B1 and produced by M. rhodorangea. In addition to its broad-spectrum antibiotic activity against Gram-positive and -negative bacteria, it also exhibits activity against eukaryotic organisms, such as protozoa and helminths [41, 49, 50] . The antileishmanial activity of G-418 (against Leishmania major and Leishmania donovani) is more potent than that of neomycin and gentamicin [39] . In addition, G-418 is used as a selective agent in cell culture protocols [51] . Antibiotics JI-20 (A and B) are also related to gentamicin production. This antibiotic was first detected during the cultivation of a mutant strain of M. echinospora JI-20 (NRRL 2953) [52] . Further, the antibacterial compound named Antibiotic 460 is produced by M. chalcea subsp. flavida NRRL 3222 [53] . [226] Sisomicin is also an aminoglycoside and has a chemical structure similar to that of gentamicin C1a, differs only in terms of the presence of an unsaturated sugar ring I, Fig. 1B [ [54] [55] [56] [57] . The antibacterial activity of sisomicin is higher than that of other structurally related aminoglycosides such as gentamicin, tobramycin and amikacin [57] . Tansarli et al. [58] reported that sisomicin displayed in vitro activity against 41% of Enterococcus spp. and 97% of Staphylococcus spp., and when applied in cream form was effective for the treatment of several diseases. Antibiotic G-52 was produced together with sisomicin by M. zionensis NRRL 5466, and is active against Gram-positive and -negative bacteria [59, 60] . Verdamicin is derived from the gray-green colonies of M. grisea NRRL 3800. This antibiotic demonstrated activity similar to that of gentamicin against members of the family Enterobacteriaceae and against Pseudomonas aeruginosa [41, 61, 62] . Sagamicin (XK-62-2), is an important antibiotic produced by soil isolates of M. sagamiensis subsp. nonreducans ATCC 21803 and M. sagamiensis ATCC 21826 [63, 64] . In 2002, Marone et al. compared the in vitro antibacterial activity of sagamicin, gentamicin, tobramycin and norfloxacin. Sagamicin was one of the most effective compounds against Enterobacteriaceae, with an MIC 90 of 2 mg/L, and exhibited good antipseudomonal activity similar to or higher than that of gentamicin [65] .
Fortimicins A, B, C, D, and KE are also aminoglycoside antibiotics produced by M. olivasterospora MK-70 (ATCC 21819) [66] [67] [68] [69] [70] . Girolami et al. (1977) , showed that the antibacterial effect of fortimicin A against Enterobacteriaceae is comparable to that of amikacin [71] . Other research reported also the bactericidal effect of Fortimicin A against Staphylococcus epidermidis [72] . Antlermicins A, B and C are antitumor antibiotics produced by a soil isolate, M. chalcea subsp. kazitnoensis T-90 [73, 74] . Tetrocarcins A, B, C, E1, E2, F and F-1, were first isolated from M. chalcea KY11091 and exhibit antibacterial activity against Gram-positive bacteria [75] [76] [77] . Tetrocarcin was effective against various experimental tumor models, such as mouse sarcoma 180 and mouse leukemia P388 [75, 78, 79] .
Combimicins, A1, A2, B1 and B2 are named after their hybrid structure of kanamycins and gentamicins. These antibiotics were obtained by growing the gentamicinproducing strain, Micromonospora sp. ATCC 31348, or its gentamicin non-producing mutant Micromonospora sp. ATCC 31349. Combimicins have strong antibacterial activities against Gram-positive and -negative bacteria [80] . AC6H is an antitumor antibiotic produced by M. carbonacea subsp. carbonacea K55-AC6. The cytotoxicity of AC6H against P388 leukemia and B16 melanoma cells was 6.25 and 25 µg/mL, respectively [81] . Marine sponge, Japan.
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Fig. 1. Chemical structure of some antibiotics produced by different Micromonospora strains. The molecular structures were downloaded from ChemSpider [356] .
Macrolide antibiotics are part of the polyketide group of natural products. The antimicrobial activity of macrolides is mediated by their binding to the 50S subunit of the bacterial ribosome, which inhibits ribosomal translocation, leading to inhibition of bacterial protein synthesis. Macrolides have also been used for the treatment of non-infectious diseases based on their anti-inflammatory and immunomodulatory effects in humans. They can inhibit the production of many pro-inflammatory cytokines, such as IL-1, IL-6, IL-8, and (TNF)-α [82] . Megalomicins A, B, C 1 and C 2 are produced by M. megalomicea strains isolated from soil. Megalomicins are characterized by antiparasitic, antibacterial and antiviral properties [83] [84] [85] [86] [87] .
Rosamicin (Rosaramicin) is an isamacrolide antibiotic produced by M. rosaria NRRL 3718 together with other minor secondary metabolites [88] [89] [90] [91] . The chemical and biological characteristics of these compounds are similar to those of erythromycin, Fig. 1C . Rosamicin exerts an antibacterial effect against Staphylococcus aureus, S. epidermidis, and enterococci [92, 93] . Juvenimicins are antibacterial antibiotics produced by M. chalcea subsp. izumensis ATCC 21561, which was initially isolated from a soil sample [94, 95] . Juvenimicin C and 5-O-α-L-rhamnosyltylactone were obtained from the culture broth of Micromonospora sp. The antibiotic Juvenimicin C increase quinone reductase 1 (QR1) enzyme and glutathione levels, which may exert a chemopreventive effect on cancer [96] .
Mycinamicins were isolated from the culture broth of M. grisseorubida A11725 [97] . This speices produces several types of mycinamicin, the structures of which have been published [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] .
The antitumor antibiotics calicheamicins (β 1Br, γ 1Br, α 2I, α 3I, β 1I, γ 1I and δ 1I) were obtained from the culture broth of M. echinospora subsp. calichensis. Calicheamicin γ 1I, Fig. 1D , exhibited antitumor activity against P388 leukemia and B16 melanoma cells in vivo. In murine tumor models, it was more effective than adriamycin, an antitumor antibiotic widely used clinically [110] [111] [112] . Calicheamicins can be used for targeted delivery by conjugation to a monoclonal antibody using a hydrazone cleavable linker [113] . This ability was used to conjugate calicheamicin with a monoclonal antibody recognizing CD33 expressed on myeloid progenitors in patients with acute myeloid leukaemia (AML), resulting in the active agent of gemtuzumab ozogamicin (Mylotarg © ). In May 2000, the U.S. Food and Drug Administration (FDA) approved this antibiotic under the accelerated approval program to treat patients who are 60 years or older suffering their first relapse with CD33+ AML and who are not considered candidates for chemotherapy [114] . However, in 2010, Pfizer Inc. announced its voluntary withdrawal from the U.S. market after questionable safety and efficacy data in post-approval studies [115] [116] [117] .
Izumenolide, Fig. 1E , is a potent inhibitor of β-lactamases, especially in Gram-negative bacteria. This antibiotic is produced by M. chalcea subsp. izumensis SC 11133 [118] [119] [120] [121] . Dotriacolide is a β-lactamase inhibitor produced by M. echinospora MG299-fF35. Dotriacolide resembles izumenolide structurally but differs in the number of Osulfate groups and the size of the lactone ring [122] . Dotriacolide was found to enhance mycinamicin production in M. griseorubida [123] .
Rustmicin (galbonolide A) is an antifungal antibiotic with an insignificant inhibitory effect on bacterial cells produced by M. chalcea 980-MC1 [124, 125] . Clostomicins (A, B 1 , B 2 , C and D) are macrolide antibiotics produced by M. echinospora subsp. armeniaca KMR-593. Clostomicins exhibited strong antibacterial activities against Gram-positive anaerobic bacteria, such as Clostridium perfringens and C. difficile [126, 127] . Quinolidomicins (A 1 , A 2 and B 1 ) were isolated from the fermentation broth of Micromonospora sp. JY16 -FERM BP-3940. Quinolidomicin A 1 inhibited the growth of various tumor cells, including multidrugresistant cells. Quinolidomicin B 1 was similarly cytotoxic, while Quinolidomicin A 2 was inactive against tumor cells [128, 129] .
Pyrrolosporin A is an antibiotic compound with antibacterial and antitumor properties. This molecule was obtained from a soil isolate of Micromonospora sp. 2C39217-R109-7 (ATCC 53791) [130] [131] [132] . Cymbimicin A and B are cyclophilin-binding structures, and were isolated from the culture broth of Micromonospora sp. A92-313709 (DSM 8594). However, cymbimicin A is more biologically active but with sixfold lower activity than cyclosporin A [133] . IB-96212 was isolated from the fermentation broth of a marine Micromonospora sp. L-25-ES25-008. This macrolide shows very strong cytotoxic activity against P388 cell lines [134, 135] . Arisostatins (A and B) are members of the tetrocarcin class of antibiotics and were isolated from the culture broth of a Micromonospora sp. TP-A0316 strain. Arisostatins showed antibiotic activity against Grampositive bacteria as well as antitumor effects [136, 137] . Arisostatin A induces apoptosis through the activation of caspase-3 and reactive oxygen species generation in AMC-HN-4 cells [138] . Micromonosporin A is a 24-membered polyene lactam macrolide isolated from the Micromonospora sp. TT1-11 [139] . Recently, Levantilide C, a 20-membered macrolide, was isolated from Micromonospora sp. FIM07-0019. Levantilide C exhibited moderate antiproliferative activity against several tumor cell lines [140] .
Everninomicins (A-E) are complex oligosaccharide antibiotics produced by M. carbonacea NRRL 2972 and M. carbonacea subsp. aurantiaca NRRL 2997 [141, 142] . The Everninomicin (SCH27899), Fig. 1F , is produced by M. carbonacea var. africana ATCC 39149 [143] . Based on an in vitro study, everninomicins B and D are active against all Gram-positive bacteria, Neisseria, and Bacteroides [144] . A multinational study involving a total of 33 laboratories demonstrated that evernimicin possesses high antimicrobial activity against Gram-positive organisms, which was higher than that of vancomycin [145] . However, the clinical development of evernimicin (Ziracin) was discontinued in Phase III clinical trials because it could not be formulated reproducibly for use as an intravenous drug [146, 147] . Trehazolin is a pseudodisaccharide, Fig. 1G , and was first isolated from the culture broth of Micromonospora sp. SANK 62390. The antibiotic effect of this compound is mediated through trehalase glycosidase inhibition activity [148] . Trehalamine was obtained by acid hydrolysis of trehazolin. It is poor inhibitor of trehalase but inhibits more potently rat intestinal sucrase (IC 50 6.8 × 10
-5 M) than trehazolin [149] .
Halomicins A, B, C and D belong to the group of ansamycin antibiotics, and are produced by M. halophytica subsp. halophytica NRRL 2998 and M. halophytica subsp. nigra NRRL 3097. These antibiotics are highly active against Gram-positive bacteria. The structure of Halomicin A is shown in Fig. 1H [41, 150, 151] . Micromonospora also produces oxazoles such as LL-E19085 alpha and citreamicins (α, β, γ, ζ and η). These compounds were isolated from the fermentation broth of M. citrea NRRL 18351 [152, 153] .
Some species of the genus Micromonospora produce thiopeptide antibiotics, such as, Sch 40832, produced by M. carbonacea var. africana ATCC 39149. This compound has potent in vitro activity against Gram-positive bacteria [154] [155] [156] . The dipeptide N-(2,6-diamino-6-hydroxymethylpimelyl)-L-alanine was isolated from the culture broth of M. chalcea PA-3534. It exhibits antibacterial activity against E. coli, and its activity is synergistically enhanced when applied with cell wall synthesis-inhibitors [157] . The amino acid L-2-(1-methylcyclopropyl)glycine, produced by M. miyakonensis PA-4046, also has antibacterial activity [158, 159] . The inhibitor of angiotensin I converting enzyme (ACE) K-13 is a cyclic dipeptide isolated from the culture broth of M. halophytica subsp. exilisia K-13 [160, 161] . The antifungal compound Sch 37137 was isolated from the culture broth of Micromonospora sp. SCC 1792 [162] . The antitumor antibiotics korkormicins are cyclic depsipeptide complexes produced by Micromonospora sp. C39500. The major component of the complex, korkormicin A, showed high in vivo antitumor activity against P388 leukemia and M109 lung carcinoma. Thus, it is considered a potential antitumor agent for cancers with wild-type p53 [163] [164] [165] [166] . Rakicidin A is a cytotoxic agent isolated from culture broth of a Micromonospora sp. R385-2 [167] [168] [169] and with a cyclic depsipeptide structure [167, 170, 171] . Thiocoraline, Fig. 1I , is a thiodepsipeptide produced by both Micromonospora sp. ACM2-092 and Micromonospora sp. ML1. It showed potent cytotoxic activity against the P-388, A-549 and MEL-28 cell lines, and exhibits strong antibacterial activity against Gram-positive bacteria [172] [173] [174] [175] . The antitumor activity of this antibiotic is mediated via DNA polymerase alpha inhibition and characterized by high cytotoxic potency against cancer cells [176, 177] . Recently, it was reported that thiocoraline exhibits cytotoxic activity in BON and H727 cells, activates the Notch pathway in carcinoids and reduces tumor progression [178, 179] . Maklamicin was obtained from the culture broth of the endophytic strain Micromonospora sp. GMKU326. It demonstrates antibacterial activity against Gram-positive bacteria [180] .
M-92 is a naphthoquinones antibiotic complex produced by M. verruculosa MCRL 0404. The six major components of this antibiotic complex have a similar antimicrobial spectrum. Among these components, VA-2 exhibited the highest antimicrobial and antitumor activities [181] [182] [183] . Another naphthoquinone, Crisamicin A, Fig. 1J , is produced by M. purpureochromogenes subsp. halotolerans RV-79-9-101. It showed in vitro activity against Gram-positive bacteria, B16 murine melanoma cells, and herpes simplex, vaccinia, and vesicular stomatitis viruses [184, 185] . 9-Hydroxycrisamicin A was extracted from the broth of Micromonospora sp. SA246. This compound exhibited antibacterial and cytotoxic activity [186] . Yoon et al. (2004) found that 9-hydroxycrisamicin-A could inactivate hepatitis B virus (HBV) replication [187] . K-259-2, an anthraquinone, is an inhibitor of Ca 2+ and calmodulin-dependent cyclic nucleotide phosphodiesterase obtained from the fermentation broth of M. olivasterospora K-259 [188] . Dynemicin A was isolated from the culture broth of M. chersina ATCC 53710 and exhibits antibacterial and cytotoxic activities [189] [190] [191] . Deoxy-dynemicin A was produced together with dynemicin A by M. globosa FERM P-10651 [192] . Lupinacidins A, B and C are produced by M. lupini Lupac 08, which was isolated from root nodules of Lupinus angustifolius collected in mid-western Spain [193, 194] . Lupinacidin C displayed potent anti-invasive activity against murine colon 26-L5 carcinoma cells [194] .
Streptonigrin and 7-(1-methyl-2 oxopropyl) streptonigrin are bioactive compounds produced by Micromonospora sp. IM 2670. Streptonigrin can induce apoptosis through a p53-dependent pathway in human neuroblastoma cells [195] . The quinocycline antibiotic kosinostatin was isolated from the culture broth of Micromonospora sp. TP-A0468, and showed antibacterial and cytotoxic activity [196, 197] . Spartanamicins A and B are antifungal anthracycline antibiotics produced by Micromonospora sp. ATCC 53803, isolated from a potted soil containing asparagus (Asparagus officinalis L.) plants [198] . Cororubicin, Fig. 1K , generated superoxide radicals in KB human epidermoid cancer cells and N18-RE-105 neuronal hybridoma cells, and showed cytotoxicity. This antibiotic is produced by Micromonospora sp. JY16, which was isolated from soil [199] . Micromonomycin is an antibacterial anthracycline compound that shows potent inhibitory activity against S. aureus, Streptococcus pneumoniae, and supersensitive E. coli, and also displayed weak antifungal activity against S. cerevisiae and C. albicans [200] . In 2012, Sousa et al. isolated Micromonospora strains associated with the tunicate Eudistoma vannamei and produces four novel anthracyclinones, two of which were cytotoxic against the human colon adenocarcinoma cell line HCT-8 [201] .
Hazimicins, a class of broad-spectrum antibiotics, were isolated from the culture broth of M. echinospora var. challisensis SCC 1411 [202] . The nucleoside antibiotics dapiramicin A and B were isolated from the fermentation broth of Micromonospora sp. SF-1917. Dapiramicin A was highly effective in the control of sheath blight, a destructive disease of rice plants caused by Rhizoctonia solani, in a pot test [203, 204] . Neihumicin was isolated from the fermentation broth of M. neihuensis Wu NH3-1 and shows in vitro cytotoxicity against KB tissue culture cells as well as antifungal activity against S. cerevisiae ATCC 9763 [205] [206] [207] . Sibanomicin is a pyrrolo-[1,4]-benzodiazepine antitumor antibiotic produced by Micromonospora sp. SF2364 [208] . Macquarimicins (A, B and C) are produced by the two strains M. chalcea AB 965S-73 and M. chalcea AB 969J-62. Macquarimicin B has inhibitory activity against the leukemia cell line P-388 [209, 210] . A naturally occurring dibenzodiazepine, BU-4664L, was produced in fermentation broth of Micromonospora sp. ATCC 55378. The compound possesses anti-inflammatory and antitumor activities [211] . The initial structure assigned for BU-4664L was revised by Igarashi et al. [212] . In 2010, Miyanaga et al. demonstrated that BU-4664L suppresses invasion and angiogenesis in vitro. It inhibited the gelatinase activities of MMP-2 and MMP-9 with IC 50 values of 0.46 and 0.60 µg/mL, respectively [213] .
YM-47515 is an isonitrile antibiotic produced by M. echinospora subsp. echinospora Y-03559J that shows antimicrobial activity against Gram-positive bacteria [214] . The antibiotic glutarimide streptimidone, Ao58A, showed high antifungal activity against several plant pathogenic fungi and inhibited the growth of Phytophthora capsici, Didymella bryoniae, Magnaporthe grisea and Botrytis cinerea with MICs in the range 3 ~ 10 µg/mL [215] . Bravomicins are obtained by fermentation of a strain of M. polytrota isolated from a soil sample. Six bioactive compounds, designated bravomicins (A-F), are obtained and found to have antibacterial activity against methicillinresistant S. aureus (MRSA) and multiply resistant E. faecium (MREF) [216] . The initial structure proposed by the US patent 5,994,543 was revised by Banskota et al. (2009) , who also suggested a strong similarity between the structures of TLN-05220, echinosporamicin and bravomicin A [217] . Staurosporine, 4'-N-methyl-5'-hydroxystaurosporine and 5'-hydroxystaurosporine are produced by the marine strain, Micromonospora sp. L-31-CLCO-002, isolated from the sponge Clathrina coriacea. These compounds showed cytotoxic activity [218] . SB-219383, a potent and selective inhibitor of bacterial tyrosyl-tRNA synthetase, was isolated from Micromonospora sp. NCIMB 40684 [219, 220] . Lomaiviticins A and B are produced by M. lomaivitiensis LL-37I366, isolated from ascidian Polysyncraton lithostrotum. Lomaiviticin A and B were demonstrated to be potent DNA damaging agents by a biochemical induction assay (BIA). Lomaiviticins C-E, were isolated recently by Woo et al. (2012) . The dimer of diazofluorene of (-)-lomaiviticin exhibits antiproliferative activity [221, 222] . The lomaiviticin A was tested against various cancer cell lines and showed cytotoxicity, with IC 50 values ranging between 0.01 and 98 ng/mL. Lomaiviticins A and B also showed antibacterial activity against Gram-positive bacteria [223] .
R176502 is an antiproliferative bafilolide metabolite extracted from liquid cultures of Micromonospora sp. JS1035 [224] . Sch725418 is a diketopiperazine isolated from Micromonospora sp. It exhibits inhibitory activity against a supersensitive strain of S. cerevisiae [225] . Echinosporamicin, an antibiotic produced by M. echinospora subsp. echinospora LL-P175, contains an aromatic polycyclic system and a piperazinone moiety. It exhibited potent activity against methicillin-resistant staphylococci and vancomycinresistant enterococci strains [226] . Diazepinomicin is a dibenzodiazepine alkaloid compound originally isolated from a marine Micromonospora sp. DPJ12 [227] . It was also produced by a Micromonospora sp. RV115 strain isolated from the sponge Aplysina aerophoba [228] . Preclinical data demonstrated that diozepinomicin is a targeted anticancer drug with dual activity: selective binding to the peripheral benzodiazepine receptor (PBR), which induces tumor apoptosis, and inhibition of the Ras/MAP kinase signaling pathway [229] . It also showed antioxidant activity against the diazepinomicinin human kidney (HK-2) and human promyelocytic (HL-60) cell lines. In addition, it exhibits antiparasitic activity against trypomastigote forms of Trypanosoma brucei, with an IC 50 of 13.5 mM [230] . Retymicin, galtamycin B, saquayamycin Z and ribofuranosyllumichrome were produced by Micromonospora sp. Tü 6368, and show cytostatic activity against several human tumor cell lines [231, 232] .
In addition to these compounds, many other antibiotics previously produced by other actinomycetes are also produced by Micromonospora. Neomycin B, which was isolated originally from Streptomyces fradiae in 1949, was also found in the culture broth of Micromonospora sp. 69-683 [233] . A comparison of the aminoglycoside acetyltransferaseencoding gene (aac), and aminoglycoside phosphoryltransferase gene (aph) of Streptomyces fradiae and Mcromonospora chalcea indicated considerable divergence [234, 235] . Other antibiotics produced by other genera were also reported in the genus Micromonospora. These include primycin [41, 236] , rifamycins [41, 237, 238] , erythromycin B [41, 239] . Actinomycins [240, 241] , bottromycins [41] and telomycin [242] [243] [244] .
Strategies for the Development of New Antibiotics from the Genus Micromonospora
Understanding how researchers identified antibiotics produced by Micromonospora strains in the past, and updating knowledge for the new analytical, biological and bioinformatics tools, can facilitate discovery of new compounds with antibiotic properties, which can reduce the cost and time required for biomolecule discovery. Fig. 2 shows the platform for discovery of potential antimicrobial compounds from the genus Micromonospora.
The source is important for the isolation of new strains that produce novel compounds. In the past, only cultured Micromonospora strains were used as sources of antibiotics, but the development of culture-independent methods increased the potential for novel molecule discovery. Using metabolomics-based tools can enable early screening to identify new molecules. Genetic engineering, metabolomic pathway engineering, bioprocess development, and biotransformation techniques are widely applied not only to increase yields of secondary metabolites but also to lead to the synthesis of new, more effective compounds. In addition, synthetic chemistry and structure modification methods are also important as components of the drug discovery platform to obtain a bioeffective final product that will be approved by the regulatory authorities.
Natural habitat of Micromonospora and research into new sources
In general, soil is the main source for the isolation of antibiotic-producing Micromonospora strains (Table 1) . Also, they have been found to be constituents of endophytic actinobacterial populations recovered from plant tissues; they are a normal occupant of actinorhizal nodules [245] . In aquatic ecosystems (freshwater and marine environments), they were isolated from water samples, sediments, and aquatic organisms such as ascidians, sponges, soft coral and molluscs [246] . From the geographical point of view, from the data presented in Table 1 , the highest numbers of antibiotic-producing Micromonospora strains were isolated from Japan and the United States. Six new species of Micromonospora discovered in 2014 were isolated in China, and one was isolated from Chinese black ant (Polyrhachis vicina Roger) [22] [23] [24] [247] [248] [249] . Biogeographic studies of the distribution of bacterial strains producing secondary metabolites are helpful for the selection of sampling coordinates [250] . For example, the recent study of CharlopPowers and his group focused on the comparative biosynthetic gene richness and diversity of 96 soil microbiomes from different soil samples in the USA. They used 454-pyroseqencing of the non-ribosomal peptide adenylation (AD) and polyketide ketosynthase (KS) domains and concluded that arid soils show the richest observed biosynthetic diversity, whereas brackish sediments and pine forest soils show the lowest [251] .
Culture-dependent approaches
The cultivation approach is still important in screening for novel natural products. Different methods of sample pretreatment and medium formulation are used in the isolation and screening of Micromonospora species. Most of these methods use the resistance of Micromonospora spores as a target [14, 17, 252, 253] . For example, sample pretreatment at 65°C for 30 min is effective for the isolation of Micromonospora colonies from estuarine sediments [254] . Bacteriophages were also applied in the screening of rare actinomycetes that can produce bioactive compounds [255] . Such new isolation methods can be useful for the cultivation of new Micromonospora strains, and include novel medium formulations, new pretreatment protocols and in situ cultivation strategies [256] . The best example is that of the isolation of the teixobactin-producing strain Eleftheria terrae using a new technique known as the isolation chip technique (iChip) [12] .
Culture-independent approaches
In the past, cultured microorganisms were the only source for natural product drug discovery, but the development of culture-independent methods has allowed further insight into drug discovery research. Metagenomics is a reliable approach to the study of microbial diversity, a measure of the potential reservoir of natural compounds and antibiotic resistance genes in the cultured and uncultured environmental microbial populations. In the same manner, metatranscriptomics and meta-proteomics can also be used. The development of next-generation deep sequencing, bioinformatics tools and available databases supports such research [257] [258] [259] [260] [261] [262] .
Metabolomics-based approaches to secondary metabolite discovery
Determination of the microbial metabolome is an important method of natural product discovery, and is supported by the recent development of tools and methods of detecting and quantifying metabolites [263] [264] [265] [266] [267] . The emergence of mass spectrometry techniques allowed the direct analysis of microbial colonies [268] . Matrix-assisted laser desorption/ ionization mass spectrometry (MALDI-TOF MS) is used for rapid identification of bacterial and fungal microorganisms [269] . MALDI-TOF MS was used for characterization of several Micromonospora species [270] . Recent research has used this method for rapid in situ detection of actinomycins in surface extracts of Streptomyces cells picked from agar plates [271] . Moreover, imaging mass spectrometry and real-time mass spectrometry facilitate identification of natural products from bacteria in the future [268] , For example, Hsu et al. (2013) used ambient electrospray ionization flow-probe to study in real-time the metabolomics of living microorganisms [268, 272] . However, the use of mass spectrometry methods for microorganisms isolated from extreme environments may encounter problems, such as the relative lack of information on such microbes in the MALDI TOF MS databases [273] . To use these methods for the identification and screening of Micromonospora strains, a comprehensive database of bioactive compounds is required for comparison. Others platforms such as nuclear magnetic resonance (NMR), gas chromatography-mass spectrometry (GC/MS), and liquid chromatography-mass spectrometry (LC/MS) are also useful for metabolomics studies. LC/MS is the most widely used method for metabolomic analysis, due to its ability to separate and detect a wide range of molecules with high sensitivity [265, 274] . Hou et al. [275] found that principal component analysis (PCA) using LC/MS was effective in the screening of marine bacterial strains with high metabolic activities and detection of new products in drug discovery programs. Micromonolactam, produced by Micromonospora sp. CMS I1-30 and Micromonospora sp. CMS I2-32, was discovered during routine chemical screening (LC-DAD-ESIMS) of a chemical fraction library of marine actinobacteria [276] . Recently, the secondary metabolite Neomacquarimicin, produced by Micromonospora sp. NPS2077, was identified during screening for secondary metabolites with a polycyclic ring system from a bacterial species by LC-MS/UV-based chemical analysis [33, 277] . In addition, metabolomics methods have been adapted for use in high-throughput discovery metabolomics platforms. Thus, it is now possible to perform mass spectrometric analysis of several hundred metabolites, with dense coverage of primary metabolism, in complex biological extracts and at throughputs of >1,000 samples per day. Indeed, the process can also be directed to specific targets such as enzyme activity [278, 279] . The recent advances in infrared and Raman spectroscopy also facilitate rapid and low cost differentiation, identification and metabolome characterization of microbial strains [280, 281] . Zhao et al. [282] studied FT-IR spectra of Micromonospora strains isolated from coastal sediments and they found that this method is good for the dereplication of environmental isolates.
Screening of biological activities
Selection of the biological target is essential before screening microorganisms program for therapeutic metabolites. The classical screening methods focused at first on antimicrobial activity (i.e., antibacterial, antifungal, anti-parasitic and antiviral). Thereafter, screening included anticancer, cytotoxic, antioxidant and anti-inflammatory activities [246, 283] . At present, screening also includes more specific targets; e.g., the antitumor antibiotics calicheamicins were discovered in a fermentation products screening program by the biochemical induction assay (BIA), which uses a genetically engineered strain of E. coli to detect DNA-damaging agents [111] . MS-444 is a naphtho [2,3-c] furan derivatives, Fig. 1L , which exhibited myosin light-chain kinase inhibition activity (MLCK), without any antimicrobial effect [284, 285] . This compound interferes with HuR RNA binding, HuR trafficking, cytokine expression and T-cell activation and shows good pharmacokinetics and low toxicity in mice [286] . Antascomicins were obtained from a screening program of more than 12,000 strains for isolation of macrophilinbinding metabolites. The most active strain was identified, named Micromonospora sp. A92-306401 and deposited in the German collection of microbes and cell culture under accession No. (DSMZ 8429). Antascomicins are structurally related to FK506 and bind strongly to FKBP12 (also known as FKBPA1), but do not show immunosuppressive activity [287] . In addition, the presence of large therapeutic target databases also facilitates the development of new biological assays [288] . Currently, due to development of high-throughput screening (HTS), concurrent screening of multiple biological activities of a large number of compounds is possible [289] .
Genomic and metabolomic pathway engineering
Determination of the gene clusters required for the biosynthesis of certain metabolites can enhance understanding of the biosynthetic pathways and thus optimize secondary metabolite production using metabolic engineering tools. The gentamicin gene cluster was sequenced [43] , which contains 32 ORFs, and 19-25 genes encode biosynthetic enzyme functions, such as gntK, a gene required for the methylation of purpurosamine C-6' in gentamicin biosynthesis [42, 44] . The assignment of functions to individual genes in the gentamicin gene cluster facilitated the study of diverse antibiotic biosynthesis pathways. Several biosynthetic pathways for production of the gentamicin C complex were proposed [43, 44, 290] . In 2014, Guo et al. provided information on late-stage biosynthesis of gentamicins from pseudo-disaccharideparomamine to the branch point at gentamicin X2, a known substrate for C-methylation at C-6' to form G418, catalyzed by the radical SAM-dependent enzyme GenK. However, this might instead undergo oxidation at C-6' to form an aldehyde, catalyzed by the GenQ flavin-linked dehydrogenase [290] . Recently, Huang et al. [291] identified four key enzymes that lead from the first-formed pseudotrisaccharide to gentamicin X2. These data can facilitate optimization of secondary metabolite production. For example, to obtain a gentamicin C1a-overproducing strain, the gacD gene was inactivated in M. echinospora. The inactivation of gacD blocks the metabolic pathways from X2 to G418 and leads to the accumulation of gentamicin C1a [292] . Through the use of combined traditional and recombinant genetic techniques, it was possible to obtain a strain with 19-fold increased G418 production and minimal by-product formation [293] .
The function of the cytochrome P450 enzyme-encoding genes rosC and rosD in the biosynthesis of rosamicin by M. rosaria was reported [294] . The production of rosamicin derivatives in M. rosaria was enhanced by the introduction of D-mycinose biosynthetic gene with the PhiC31-derived integration vector pSET152 [295] . Recent research also showed that the introduction of d-mycinose biosynthesis genes in the mycinamicin II biosynthesis gene cluster of M. guriseorubida A11725 into rosC and rosD-disrupted mutants of M. rosaria IFO13697 enhanced the production process. The resulting engineered strains, M. rosaria TPMA0054 and TPMA0069, produced mycinosyl rosamicin derivatives, IZIV and IZV, respectively. IZIV was identified as a novel mycinosyl rosamicin derivative, 23-O-mycinosyl-20-deoxo-20-dihydrorosamicin [296] . Using genome scanning data of the hazimicin producer, M. echinospora ssp. challisensis NRRL 12255, enabled isolation TLN-05220 and TLN-05223, which have cytotoxic activities against various human tumor cell lines [217] .
Other gene clusters and biosynthetic pathways of Micromonospora antibiotics have been reported, such as the thiocoraline biosynthetic gene cluster [297] [298] [299] and evernimicin biosynthetic gene cluster of M. carbonacea var. africana ATCC39149 [143] , the mycinamycin gene cluster and biosynthetic pathway [300] [301] [302] [303] , and the diazepinomicin biosynthetic pathway [304] [305] [306] . More recently, the methionine gamma-lyase gene in the calicheamicin biosynthesis gene cluster of M. echinospora was identified [307] .
Bioprocess development and biotransformation
The aim of bioprocess development is to increase secondary metabolite yields. Bioprocesses are influenced by several factors, from the culture medium (nutrient composition and concentrations), to cultivation parameters (temperature, pH, agitation, aeration, etc.) [308] [309] [310] . Therefore, these parameters must be optimized for maximal yield using different approaches and also to transfer the process from the laboratory scale to the pilot and large-scale bioreactor levels.
For example, gentamicin is manufactured through a complex process using Micromonospora strains. In general, gentamicin is produced by submerged fermentation. Optimization of the production medium is an empirical process, as medium must be economic with a high production yield. Also, it is important to use ingredients that assist downstream processes [311] . Different carbon sources were used in gentamicin production, such as starch, sucrose, and soybean oil [312] [313] [314] [315] [316] . Nitrogen sources are important for cell growth and antibiotic production. Soybean meal, yeast extract, peptone and corn steep liquor have been reported to be suitable substrates for gentamicin production [312, 313, 317, 318] . Di-potassium phosphate (K 2 HPO 4 ) is a common source of phosphate, and is essential for growth and antibiotic production [311] . Cobalt is a prerequisite for gentamicin synthesis. Charney et al. [312] found that medium must contain at least 0.01 µg/mL cobalt (as CoCl 2 .6H 2 O), which is equivalent to 2.5 × 10 -9 g/mL cobalt. In 2006, Himabindu et al. [315] used the response surface methodology (RSM) for medium optimization to increase gentamicin production by M. echinospora ATCC 15838. They found that a medium with starch (9 g/L), soybean meal (3 g/L), K 2 HPO 4 (0.9 g/L) and CoCl 2 (0.001 g/L) yielded 880 mg/L of gentamicin. However, the problem with use of complex medium components is seasonal variations and chemical composition consistency, which affect the yield [311, 319] . The pH of the culture medium can affect growth and gentamicin production in submerged cultures. Charney et al. [312] , found that the optimal pH for production lies between 6.9 and 7.0. Abou-zeid and Eissa [313] reported that the most suitable initial pH for antibiotic production was between 7 and 7.5. Dissolved oxygen (DO) is also a critical limiting factor for growth and gentamicin production. Gentamicin production peaks at a DO level of 40% saturation [311, 320] . In addition, physiological status and inoculum size also play a critical role in gentamincin production [311, 321] .
In general, gentamicin is produced intracellularly. Various physical and chemical approaches have been used to extract the antibiotic from cells. Among them, ultrasonic treatment is the most efficient [317, 322] . However, for large-scale production, gentamycins are usually recovered by adsorption, solvent extraction, and crystallization [311] . One of the first reports of gentamicin purification was the work of Luedemann and Weinstein in 1963, in which they used cationic and anionic exchange adsorption columns and methanol extraction for purification of gentamicin [323] . As gentamicin is a complex consisting of several minor and three major components, the proportions of these components can vary depending on the fermentation process, and some of the impurities are toxic [311, 324] . Therefore, the pharmaceutical industry is earger to develop more powerful methods of separation. In 2012, Grote et al. [324] described a method for synthesis of a single conjugate of gentamicin. They found that reaction of the gentamicin complex with excess benzyl chloroformate provided a mixture of amine-protected components, which can be separated by preparative HPLC using UV detection, which facilitates production of a single gentamicin conjugate.
Gentamicin is administered intravenously, and its bactericidal activity is concentration-dependent. Therefore, the dose used should be carefully adjusted. Also, gentamicin is not metabolized and eliminated by the kidneys, and overdoses can increase the risk of renal toxicity and ototoxicity [325, 326] . Routinely, in the pharmaceutical industry, and because of the chemical nature of the gentamicin complex, only the relative percentages of its major constituents are measured by liquid chromatography combined with pulsed electrochemical detection (LC-PED). Microbiological assays, immunoassays and ELISAs can also be used in gentamicin analysis [327] . Li et al. [328] reported a LC-PED method with a reversed-phase C18 column and a mobile phase consisting of trifluoroacetic acid (TFA), pentafluoropropionic acid (PFPA), sodium hydroxide and acetonitrile, which showed better separation and more sensitive detection of gentamicin components than a method using a polymer column. Vucicevic-Prcetic et al. [327] , developed a new analytical method for the determination of gentamicin based on liquid chromatography with tandem mass spectrometry (LC/MS/MS), which enabled complete baseline separation of components C 1 , C 1a , C 2 , C 2a and C 2b according to the European and British Pharmacopoeias.
The biotransformation approach also enables the modification of existing antibiotic molecules to create new therapeutic agents. The addition of analogues of 2-deoxystreptamine to the M. inyoensis NRRL 3292 mutant, a sisomicin-producing organism, resulted in the formation of new antibiotics known as mutamicins [329] . Mutamicin 1 was produced by the addition of streptamine to the fermentation broth, and mutamicin 2 was produced by the addition of 2, 5-dideoxystreptamine [329] . Other research showed that employing a recombinant Streptomyces venezuelae strain as a microbial catalyst, a reduced macrolide, 10, 11-dihydrorosamicin, was created from the macrolide rosamicin. The new rosamicin analog showed two-to four-fold higher antibacterial activity against two strains of methicillinresistant S. aureus compared to its parent rosamicin [330] . In the presence of serum, rustmicin rapidly epimerizes at the C-2 position and is converted to a γ-lactone, a product that is devoid of activity. To synthesize derivatives of rustmicin with improved chemical stability and antifungal activity, Shafiee et al. [331, 332] , used Streptomyces halstedii to synthesize more stable compounds by microbial hydroxylation.
Synthetic chemistry and structure modification
In many cases, it is difficult to use antibiotics with their original structure directly as therapeutic agents. This is due to the development of antibiotic-resistant strains, cytoxicity, and improper pharmacokinetic and pharmacodynamics. For example, gentamicin C1a can be used as a starting material for etimicin production, which is an antibiotic active against drug-resistant bacteria that exhibits antimicrobial activity against both Gram-positive and Gram-negative bacteria [333, 334] . Isepamicin is a semi-synthetic derivative of gentamicin B, which possesses a high level of stability to aminoglycoside-inactivating enzymes and low levels of toxicity to the kidney and inner ear. In addition, isepamicin is active against Gram-negative bacteria resistant to amikacin and other aminoglycosides [335] [336] [337] . Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomicin with similar activity to gentamicin, but lower toxicity [338] . Plazomicin was synthetically derived from sisomicin by appending a hydroxy-aminobutyric acid substituent at position 1 and a hydroxyethyl substituent at position 6'. It is characterized by dose-dependent activity against both Gram-positive and -negative pathogens [339] [340] [341] . In addition, the derivative 6'-hydroxysisomicin exhibits promising activity against a broad range of protozoan parasites [342] . Thiochoraline can be chemically synthesized [343, 344] , and various derivatives can be produced from thiocoraline, such as the antitumor antibiotics NMe-azathiocoraline and oxathiocoraline [345] [346] [347] . MS-444 and Rakicidin A have also been successfully chemically synthesized [171, 348] .
Future Perspectives
The genus Micromonospora had been the source of many drugs, some of them, such as gentamicin, are considered essential to global health [46] . Although there were some disappointments, despite the large number of papers and patents published, few bioactive molecules from this group of microorganisms have reached the market. In many cases, the drug development process was terminated at the clinical trial level, such as in case of evernimicin and rosaramicin [147] . However, new legislation and investment in biotechnology can assist antibiotic development. In the last decade, 11 new antibiotics were approved, including 4 in 2014 alone [9, 349] . The biopharmaceutical industry must adapt to the global antibacterial drugs market, which will reach an estimated value of $45.09 billion in 2019 [350] , and the current prescription data suggest that aminoglycosides as antimicrobials represent a >$500 million market in the U.S. That is why some biopharmaceutical companies have acquired intellectual property rights covering next-generation antibiotic derivatives, which retain the biological activity but are less cytotoxic [350, 351] . Also, reviving old antibiotics could be a good approach [352] . With the recent advances in screening program management, and the availability of more sophisticated analytical, biological and bioinformatics tools, the study of the genus Micromonospora is still important for discovery of new therapeutic agents. Investigation of new sources and the use of innovative methods will facilitate the discovery of novel antibiotics from the genus Micromonospora.
